glioblastoma

  • May 30, 2020  

    China NMPA Approves Optune for the Treatment of Newly Diagnosed and Recurrent Glioblastoma Bookmark

    George Lundberg, MD

    Press release from Novocure curated by Editor in Chief George Lundberg, MD, who notes: 

    Chinese doctors managing one the most difficult tumors to treat, glioblastoma (GBM), now have another approved option, Optune, after favorable clinical trial results. The method has been previously approved by the U.S. Food and Drug Administration.

    Go to full article published by Novocure on Business Wire.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020  

    No OS Boost With Opdivo in Recurrent Glioblastoma Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • April 21, 2020  

    5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the Two Techniques to Optimize the Extent of Resection in Glioblastoma Surgery Bookmark

    George Lundberg, MD

    Research paper from Neurosurgery curated by Editor in Chief George Lundberg, MD, who notes: 

    The best chance a patient has for survival with glioblastoma is the extent to which the tumor is initially removed surgically. The tools discussed in this study can help the surgeon maximize extirpation.

    Go to full paper published in Neurosurgery.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • February 22, 2020  

    Predicting Prognosis in Glioblastoma Bookmark

    George Lundberg, MD

    Article from The Pathologist curated by Editor in Chief George Lundberg, MD, who notes: 

    Liquid biopsy shows surprising apparent prognostic value in glioblastoma multiforme (GBM).

    Go to full article published by The Pathologist.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • February 22, 2020  

    Data Favor Max Resection for All Glioblastomas Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    A large, retrospective study demonstrates that surgical removal of as much tumor tissue as possible results in the best outcomes for patients—seems pretty logical, and is true.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Biological Activity of Weekly ONC201 in Adult Recurrent Glioblastoma Patients Bookmark

    George Lundberg, MD

    Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    This paper reports the results of an investigation of the drug ONC201 in adults with recurrent glioblastoma (GBM). It found that ONC201 penetrated the blood-brain barrier and achieved intratumoral levels without toxicity. While most GBMs were not responsive, one patient with the mutation H3 K27M experienced a prolonged remission.

    Go to full paper published in Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • September 16, 2019  

    Fixed and Variable Factors that Impact a Brain Tumor Patient’s Prognosis

    George Lundberg, MD

    A Q&A with Burt Nabors, MD, Professor and Director of the Division of Neuro-oncology at the University of Alabama, Birmingham, and a member of the Cancer Commons Brain Tumor Advisory Board; bnabors@uabmc.edu Q: Primary brain gliomas can be devastating, often deadly, malignancies. Obvious prognostic factors include whether they are grade 1, 2, 3, or 4; their extent of growth prior to diagnosis (stage); and… Read more »

  • August 26, 2019  

    The Importance of Brain Tumor-Initiating Cells in Glioblastoma

    With: Anita Hjelmeland, PhD

    A Q&A with Anita Hjelmeland, PhD, Associate Professor of Cell, Developmental and Integrative Biology at the University of Alabama Birmingham School of Medicine; hjelmea@uab.edu Q: The inner workings of malignant gliomas are mysterious to many of us. Why does the prognosis of patients with these tumors remain poor? A: Glioblastoma is a primary brain tumor that is treated with surgery, radiation, and chemotherapy. While… Read more »